DUBLIN--(BUSINESS WIRE)--The "Central Nervous Systems Therapeutic Drug Monitoring - Medical Devices Pipeline Assessment, 2019" report has been added to ResearchAndMarkets.com's offering.
This report provides an overview of Central Nervous Systems Therapeutic Drug Monitoring currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Central Nervous Systems Therapeutic Drug Monitoring pipeline products.
Scope
- Extensive coverage of the Central Nervous Systems Therapeutic Drug Monitoring under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Central Nervous Systems Therapeutic Drug Monitoring and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Central Nervous Systems Therapeutic Drug Monitoring under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Key Topics Covered
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Central Nervous Systems Therapeutic Drug Monitoring Overview
3 Products under Development
3.1 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Stage of Development
3.2 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Territory
3.3 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Regulatory Path
3.4 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Estimated Approval Date
4 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products under Development by Companies
4.1 Central Nervous Systems Therapeutic Drug Monitoring Companies - Pipeline Products by Stage of Development
4.2 Central Nervous Systems Therapeutic Drug Monitoring - Pipeline Products by Stage of Development
5 Central Nervous Systems Therapeutic Drug Monitoring Companies and Product Overview
5.1 Abbott Diagnostics
5.2 ARK Diagnostics Inc.
5.3 Avacta Group PLC
5.4 ELITechGroup Inc.
5.5 Nipro Europe N.V.
5.6 Pax Neuroscience Inc.
5.7 Saladax Biomedical Inc.
5.8 Siemens Healthineers AG
5.9 University of Colorado
6 Central Nervous Systems Therapeutic Drug Monitoring - Recent Developments
6.1 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership
6.2 Jul 29, 2019: Siemens Healthineers continues to drive growth forward
6.3 Jul 29, 2019: Changes in the Managing Board of Siemens Healthineers
6.4 May 02, 2019: Siemens Healthineers posts strong revenue and profit growth in the second quarter
6.5 Apr 09, 2019: Avacta Group: Interim results for the period ended 31 January 2019
6.6 Feb 11, 2019: Siemens Healthineers to invest EUR 350 million in new Campus Forchheim
6.7 Jan 28, 2019: Avacta Group names Dr Sam Williams as Non-Executive Director to the Board
6.8 Jan 21, 2019: Avacta Group announced its AGM business update and a notice of results
6.9 Dec 12, 2018: Avacta Group names Dr. Jose Saro as Chief Medical Officer
6.10 Dec 04, 2018: 10 Billion Lab Tests and Growing: Siemens Healthineers Mass. Manufacturing Expansion Largely Completed
6.11 Dec 04, 2018: 10 billion lab tests and growing: Siemens Healthineers mass. manufacturing expansion largely completed
6.12 Nov 05, 2018: Siemens Healthineers with a strong finish in the fourth quarter, full year targets for fiscal 2018 achieved
6.13 Oct 23, 2018: Leading Homegrown Medical Group, MWH Medical partners Siemens Healthineers to launch region's first Asia Reference Centre
For more information about this report visit https://www.researchandmarkets.com/r/bed8fy
